{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:15:11Z","timestamp":1791918911548,"version":"4.3.4"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00210-024-03599-2","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T07:49:39Z","timestamp":1732607379000},"page":"3489-3511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Flavopiridol: a promising cyclin-dependent kinase inhibitor in cancer treatment"],"prefix":"10.1007","volume":"398","author":[{"given":"Uttam Singh","family":"Baghel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Kriplani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Meghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhawani","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William N.","family":"Setzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Sharifi-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Calina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"3599_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.14235\/bas.galenos.2019.3491","volume":"8","author":"E A\u00e7ikg\u00f6z","year":"2020","unstructured":"A\u00e7ikg\u00f6z E, G\u00fcler G, \u00d6ktem G (2020) Effect of flavopiridol on cell cycle, apoptosis and biomolecule structure changes in breast cancer stem cells. Bezmialem Sci 8:275","journal-title":"Bezmialem Sci"},{"key":"3599_CR3","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/annonc\/mdg343","volume":"14","author":"M Aklilu","year":"2003","unstructured":"Aklilu M, Kindler H, Donehower R, Mani S, Vokes E (2003) Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 14:1270\u20131273","journal-title":"Ann Oncol"},{"key":"3599_CR4","unstructured":"Arguello F, Alexander M, Sterry JA, Tudor G, SMITH EM, Kalavar NT, Greene Jr JF, Koss W, Morgan CD, Stinson SF (1998) Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood, the Journal of the American Society of Hematology 91:2482-2490"},{"key":"3599_CR5","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00277-016-2683-1","volume":"95","author":"FT Awan","year":"2016","unstructured":"Awan FT, Jones JA, Maddocks K, Poi M, Grever MR, Johnson A, Byrd JC, Andritsos LA (2016) A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy. Ann Hematol 95:1137\u20131143","journal-title":"Ann Hematol"},{"key":"3599_CR6","first-page":"4856","volume":"56","author":"KC Bible","year":"1996","unstructured":"Bible KC, Kaufmann SH (1996) Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Can Res 56:4856\u20134861","journal-title":"Can Res"},{"key":"3599_CR7","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/leu.2011.109","volume":"25","author":"KA Blum","year":"2011","unstructured":"Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M (2011) Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia 25:1444\u20131451","journal-title":"Leukemia"},{"key":"3599_CR8","doi-asserted-by":"crossref","unstructured":"Bozok Cetintas V, Acikgoz E, Yigitturk G, Demir K, Oktem G, Tezcanli Kaymaz B, Oltulu F, Aktug H (2016) Effects of flavopiridol on critical regulation pathways of CD133high\/CD44high lung cancer stem cells. Medicine (Baltimore) 95:e5150","DOI":"10.1097\/MD.0000000000005150"},{"key":"3599_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1023\/B:DRUG.0000026258.02846.1c","volume":"22","author":"S Burdette-Radoux","year":"2004","unstructured":"Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst DS, Walsh W, Wainman N, Colevas AD, Eisenhauer EA (2004) Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 22:315\u2013322","journal-title":"Invest New Drugs"},{"key":"3599_CR10","first-page":"3804","volume":"92","author":"JC Byrd","year":"1998","unstructured":"Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, Flinn IW, Diehl LF, Sausville E, Grever MR (1998) Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood, the Journal of the American Society of Hematology 92:3804\u20133816","journal-title":"Blood, the Journal of the American Society of Hematology"},{"key":"3599_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/1535-7163.409.3.4","volume":"3","author":"K Camphausen","year":"2004","unstructured":"Camphausen K, Brady KJ, Burgan WE, Cerra MA, Russell JS, Bull EE, Tofilon PJ (2004) Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci. Mol Cancer Ther 3:409\u2013416","journal-title":"Mol Cancer Ther"},{"key":"3599_CR12","first-page":"2973","volume":"56","author":"BA Carlson","year":"1996","unstructured":"Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ (1996) Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Can Res 56:2973\u20132978","journal-title":"Can Res"},{"key":"3599_CR13","doi-asserted-by":"publisher","first-page":"28345","DOI":"10.1074\/jbc.C000446200","volume":"275","author":"S-H Chao","year":"2000","unstructured":"Chao S-H, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, Peterlin BM, Price DH (2000) Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 275:28345\u201328348","journal-title":"J Biol Chem"},{"key":"3599_CR14","doi-asserted-by":"publisher","first-page":"31793","DOI":"10.1074\/jbc.M102306200","volume":"276","author":"S-H Chao","year":"2001","unstructured":"Chao S-H, Price DH (2001) Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 276:31793\u201331799","journal-title":"J Biol Chem"},{"key":"3599_CR15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jconrel.2021.03.042","volume":"333","author":"KT Chen","year":"2021","unstructured":"Chen KT, Militao GG, Anantha M, Witzigmann D, Leung AW, Bally MB (2021a) Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia. J Control Release 333:246\u2013257","journal-title":"J Control Release"},{"key":"3599_CR16","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1182\/blood-2005-04-1678","volume":"106","author":"R Chen","year":"2005","unstructured":"Chen R, Keating MJ, Gandhi V, Plunkett W (2005a) Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106:2513\u20132519","journal-title":"Blood"},{"key":"3599_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00280-015-2772-1","volume":"76","author":"D Cihalova","year":"2015","unstructured":"Cihalova D, Staud F, Ceckova M (2015) Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro. Cancer Chemother Pharmacol 76:105\u2013116","journal-title":"Cancer Chemother Pharmacol"},{"key":"3599_CR18","doi-asserted-by":"crossref","unstructured":"Cimini A, D Angelo M, Benedetti E, D'Angelo B, Laurenti G, Antonosante A, Cristiano L, Di Mambro A, Barbarino M, Castelli V, Cinque B, Cifone MG, Ippoliti R, Pentimalli F, Giordano A (2016) Flavopiridol: an old drug with new perspectives? Implication for development of new drugs. J Cell Physiol 232:312-322","DOI":"10.1002\/jcp.25421"},{"key":"3599_CR19","doi-asserted-by":"crossref","unstructured":"Da Cunha AR, Compton K, Xu RX, Mishra R, Drangsholt MT, Antunes JLF, Kerr AR, Acheson AR, Lu D, Wallace LE, Kocarnik JM, Fu WJ, Dean FE, Pennini A, Henrikson HJ, Alam T, Ababneh E, Abd-Elsalam S, Abdoun M, Abidi H, Ali HA, Abu-Gharbieh E, Adane TD, Addo IY, Ahmad A, Ahmad S, Rashid TA, Akonde M, Al Hamad H, Alahdab F, Alimohamadi Y, Alipour V, Al-Maweri SA, Alsharif U, Ansari-Moghaddam A, Anwar SL, Anyasodor AE, Arabloo J, Aravkin AY, Aruleba RT, Asaad M, Ashraf T, Athari SS, Attia S, Azadnajafabad S, Azangou-Khyavy M, Badar M, Baghcheghi N, Banach M, Bardhan M, Barqawi HJ, Bashir NZ, Bashiri A, Benzian H, Bernabe E, Bhagat DS, Bhojaraja VS, Bjorge T, Bouaoud S, Braithwaite D, Briko NI, Calina D, Carreras G, Chakraborty PA, Chattu VK, Chaurasia A, Chen MX, Cho WCS, Chu DT, Chukwu IS, Chung ENC, Cruz-Martins N, Dadras O, Dai XC, Dandona L, Dandona R, Daneshpajouhnejad P, Soltani RDC, Darwesh AM, Debela SA, Molla MD, Dessalegn FN, Dianati-Nasab M, Digesa LE, Dixit SG, Dixit A, Djalalinia S, El Sayed I, El Tantawi M, Enyew DB, Erku DA, Ezzeddini R, Fagbamigbe AF, Falzone L, Fetensa G, Fukumoto T, Gaewkhiew P, Gallus S, Gebrehiwot M, Ghashghaee A et al (2023) The global, regional, and national burden of adult lip, oral, and pharyngeal cancer in 204 countries and territories\u00a0a systematic analysis for the global burden of disease study 2019. Jama Oncol 9:1401-1416","DOI":"10.1001\/jamaoncol.2023.2960"},{"key":"3599_CR20","doi-asserted-by":"crossref","unstructured":"De Azevedo Jr WF, Mueller-Dieckmann H-J, Schulze-Gahmen U, Worland PJ, Sausville E, Kim S-H (1996) Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci 93:2735-2740","DOI":"10.1073\/pnas.93.7.2735"},{"key":"3599_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/sj.cdd.4400868","volume":"8","author":"R Decker","year":"2001","unstructured":"Decker R, Dai Y, Grant S (2001) The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ 8:715\u2013724","journal-title":"Cell Death Differ"},{"key":"3599_CR22","doi-asserted-by":"publisher","first-page":"18500","DOI":"10.1039\/C8NJ04306J","volume":"42","author":"A Deep","year":"2018","unstructured":"Deep A, Marwaha RK, Marwaha MG, Nandal R, Sharma AK (2018) Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review. New J Chem 42:18500\u201318507","journal-title":"New J Chem"},{"key":"3599_CR23","first-page":"273","volume":"3","author":"M Drees","year":"1997","unstructured":"Drees M, Dengler WA, Roth T, Labonte H, Mayo J, Malspeis L, Grever M, Sausville EA, Fiebig HH (1997) Flavopiridol (L86\u20138275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res: an Official Journal of the American Association for Cancer Research 3:273\u2013279","journal-title":"Clin Cancer Res: an Official Journal of the American Association for Cancer Research"},{"key":"3599_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/vco.12130","volume":"14","author":"Y Ema","year":"2016","unstructured":"Ema Y, Igase M, Takeda Y, Yanase T, Umeki S, Hiraoka H, Okuda M, Mizuno T (2016) Investigation of the cytotoxic effect of flavopiridol in canine lymphoma cell lines. Vet Comp Oncol 14:95\u2013106","journal-title":"Vet Comp Oncol"},{"key":"3599_CR25","first-page":"6433","volume":"14","author":"A Erol","year":"2017","unstructured":"Erol A, Acikgoz E, Guven U, Duzagac F, Turkkani A, Colcimen N, Oktem G (2017) Ribosome biogenesis mediates antitumor activity of flavopiridol in CD44+\/CD24-breast cancer stem cells. Oncol Lett 14:6433\u20136440","journal-title":"Oncol Lett"},{"issue":"2","key":"3599_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3390\/cancers14020293","volume":"14","author":"T Ettl","year":"2022","unstructured":"Ettl T, Schulz D, Bauer RJ (2022) The renaissance of cyclin dependent kinase inhibitors. Cancers 14(2):293. https:\/\/doi.org\/10.3390\/cancers14020293","journal-title":"Cancers"},{"key":"3599_CR27","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.leukres.2005.03.010","volume":"29","author":"IW Flinn","year":"2005","unstructured":"Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K, Petric R, Ramon-Suerez J (2005) Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 29:1253\u20131257","journal-title":"Leuk Res"},{"key":"3599_CR28","doi-asserted-by":"publisher","first-page":"601626","DOI":"10.3389\/fphar.2021.601626","volume":"12","author":"A Gagliardi","year":"2021","unstructured":"Gagliardi A, Giuliano E, Venkateswararao E, Fresta M, Bulotta S, Awasthi V, Cosco D (2021) Biodegradable polymeric nanoparticles for drug delivery to solid tumors. Front Pharmacol 12:601626","journal-title":"Front Pharmacol"},{"key":"3599_CR29","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/leu.2014.40","volume":"28","author":"M Garcia-Cuellar","year":"2014","unstructured":"Garcia-Cuellar M, F\u00fcller E, M\u00e4thner E, Breitinger C, Hetzner K, Zeitlmann L, Borkhardt A, Slany R (2014) Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia. Leukemia 28:1427\u20131435","journal-title":"Leukemia"},{"key":"3599_CR30","first-page":"3527","volume":"8","author":"I Gojo","year":"2002","unstructured":"Gojo I, Zhang B, Fenton RG (2002) The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 8:3527\u20133538","journal-title":"Clin Cancer Res"},{"key":"3599_CR31","doi-asserted-by":"publisher","first-page":"104161","DOI":"10.1016\/j.drudis.2024.104161","volume":"29","author":"Y Guo","year":"2024","unstructured":"Guo Y, Ashrafizadeh M, Tambuwala MM, Ren J, Orive G, Yu G (2024) P-glycoprotein (P-gp)-driven cancer drug resistance: biological profile, non-coding RNAs, drugs and nanomodulators. Drug Discov Today 29:104161","journal-title":"Drug Discov Today"},{"key":"3599_CR32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0040-4039(01)93556-7","volume":"20","author":"AD Harmon","year":"1979","unstructured":"Harmon AD, Weiss U, Silverton J (1979) The structure of rohitukine, the main alkaloid of Amoora rohituka (syn. Aphanamixis polystachya)(Meliaceae). Tetrahedron Lett 20:721\u2013724","journal-title":"Tetrahedron Lett"},{"key":"3599_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00280-013-2347-y","volume":"73","author":"CC Hofmeister","year":"2014","unstructured":"Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J (2014) A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer Chemother Pharmacol 73:249\u2013257","journal-title":"Cancer Chemother Pharmacol"},{"key":"3599_CR34","doi-asserted-by":"publisher","unstructured":"Huang M-Y, Zhang L-L, Ding J, Lu J-J (2018) Anticancer drug discovery from Chinese medicinal herbs. Chin Med 13:35.\u00a0https:\/\/doi.org\/10.1186\/s13020-018-0192-y","DOI":"10.1186\/s13020-018-0192-y"},{"key":"3599_CR35","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1182\/blood-2007-10-115733","volume":"111","author":"SR Hussain","year":"2008","unstructured":"Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Dang VX, Viatchenko-Karpinski S, Ruppert AS, Byrd JC, Kuppusamy P, Crouser ED, Grever MR (2008) Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 111:3190\u20133199","journal-title":"Blood"},{"key":"3599_CR36","doi-asserted-by":"publisher","first-page":"112355","DOI":"10.1016\/j.ejmech.2020.112355","volume":"199","author":"N Ibrahim","year":"2020","unstructured":"Ibrahim N, Bonnet P, Brion J-D, Peyrat J-F, Bignon J, Levaique H, Josselin B, Robert T, Colas P, Bach S (2020) Identification of a new series of flavopiridol-like structures as kinase inhibitors with high cytotoxic potency. Eur J Med Chem 199:112355","journal-title":"Eur J Med Chem"},{"key":"3599_CR37","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/pbc.21386","volume":"50","author":"KM Jackman","year":"2008","unstructured":"Jackman KM, Frye CB, Hunger SP (2008) Flavopiridol displays preclinical activity in acute lymphoblastic leukemia. Pediatr Blood Cancer 50:772\u2013778","journal-title":"Pediatr Blood Cancer"},{"key":"3599_CR38","doi-asserted-by":"crossref","unstructured":"Jafari A, Babajani A, Sarrami Forooshani R, Yazdani M, Rezaei-Tavirani M (2022) Clinical applications and anticancer effects of antimicrobial peptides: from bench to bedside. Front Oncol 12:819563","DOI":"10.3389\/fonc.2022.819563"},{"key":"3599_CR39","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ejmech.2018.05.004","volume":"152","author":"L Jalili-Baleh","year":"2018","unstructured":"Jalili-Baleh L, Babaei E, Abdpour S, Bukhari SNA, Foroumadi A, Ramazani A, Sharifzadeh M, Abdollahi M, Khoobi M (2018) A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer\u2019s disease. Eur J Med Chem 152:570\u2013589","journal-title":"Eur J Med Chem"},{"key":"3599_CR40","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1158\/1078-0432.CCR-12-1092","volume":"19","author":"J Ji","year":"2013","unstructured":"Ji J, Mould DR, Blum KA, Ruppert AS, Poi M, Zhao Y, Johnson AJ, Byrd JC, Grever MR, Phelps MA (2013) A pharmacokinetic\/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridolA PK\/PD model of TLS in CLL patients receiving flavopiridol. Clin Cancer Res 19:1269\u20131280","journal-title":"Clin Cancer Res"},{"issue":"22","key":"3599_CR41","doi-asserted-by":"publisher","first-page":"7530","DOI":"10.3390\/molecules28227530","volume":"28","author":"H Joshi","year":"2023","unstructured":"Joshi H, Tuli HS, Ranjan A, Chauhan A, Haque S, Ramniwas S, Bhatia GK, Kandari D (2023) The pharmacological implications of flavopiridol: an updated overview. Molecules 28(22):7530. https:\/\/doi.org\/10.3390\/molecules28227530","journal-title":"Molecules"},{"key":"3599_CR42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1006\/abbi.2000.2220","volume":"386","author":"A Kaiser","year":"2001","unstructured":"Kaiser A, Nishi K, Gorin FA, Walsh DA, Bradbury EM, Schnier JB (2001) The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase. Arch Biochem Biophys 386:179\u2013187","journal-title":"Arch Biochem Biophys"},{"key":"3599_CR43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127\u2013132","journal-title":"Nat Biotechnol"},{"key":"3599_CR44","doi-asserted-by":"publisher","first-page":"8403","DOI":"10.1158\/1078-0432.CCR-05-1201","volume":"11","author":"JE Karp","year":"2005","unstructured":"Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, Colevas AD, Bauer KS (2005) Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res 11:8403\u20138412","journal-title":"Clin Cancer Res"},{"key":"3599_CR45","first-page":"307","volume":"9","author":"JE Karp","year":"2003","unstructured":"Karp JE, Ross DD, Yang W, Tidwell ML, Wei Y, Greer J, Mann DL, Nakanishi T, Wright JJ, Colevas AD (2003) Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. Clin Cancer Res 9:307\u2013315","journal-title":"Clin Cancer Res"},{"key":"3599_CR46","doi-asserted-by":"crossref","unstructured":"Kelland LR (2000) Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin Investig Drugs 9:2903-2911","DOI":"10.1517\/13543784.9.12.2903"},{"key":"3599_CR47","first-page":"15","volume":"1","author":"ABR Khalipha","year":"2019","unstructured":"Khalipha ABR, Bagchi R, Hossain MS, Mondal M, Biswas S, Ray P, Smrity SZ, Asha UH (2019) A literature based review on rohitukine and molecular docking studies of flavopiridol (rohitukine derived) and its derivatives against cyclin-dependent kinases (CDKs) for anticancer activity. Int J Sci Res 1:15\u201328","journal-title":"Int J Sci Res"},{"key":"3599_CR48","first-page":"621","volume":"63","author":"DM Kim","year":"2003","unstructured":"Kim DM, Koo SY, Jeon K, Kim MH, Lee J, Hong CY, Jeong S (2003) Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res 63:621\u2013626","journal-title":"Cancer Res"},{"key":"3599_CR49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4143\/crt.2005.37.3.191","volume":"37","author":"S Kim","year":"2005","unstructured":"Kim S, Wu HG, Shin JH, Park HJ, Kim IA, Kim IH (2005) Enhancement of radiation effects by flavopiridol in uterine cervix cancer cells. Cancer Res Treat 37:191\u2013195","journal-title":"Cancer Res Treat"},{"key":"3599_CR50","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.tet.2017.12.052","volume":"74","author":"R Kshatriya","year":"2018","unstructured":"Kshatriya R, Jejurkar VP, Saha S (2018) In memory of Prof. Venkataraman: recent advances in the synthetic methodologies of flavones. Tetrahedron 74:811\u2013833","journal-title":"Tetrahedron"},{"key":"3599_CR51","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-16-2629","volume":"23","author":"C Lacerte","year":"2017","unstructured":"Lacerte C, Ivaturi V, Gobburu J, Greer JM, Doyle LA, Wright JJ, Karp JE, Rudek MA (2017) Exposure\u2013response analysis of alvocidib (flavopiridol) treatment by bolus or hybrid administration in newly diagnosed or relapsed\/refractory acute leukemia patientspharmacometric analysis of flavopiridol treatment. Clin Cancer Res 23:3592\u20133600","journal-title":"Clin Cancer Res"},{"key":"3599_CR52","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrd2907","volume":"8","author":"S Lapenna","year":"2009","unstructured":"Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8:547\u2013566","journal-title":"Nat Rev Drug Discov"},{"key":"3599_CR53","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood.V106.11.944.944","volume":"106","author":"TS Lin","year":"2005","unstructured":"Lin TS, Fischer B, Moran ME, Buckner MM, Shank R, Kraut EH, Porcu P, Farag SS, Eisenbeis CF, Colevas D (2005) Flavopiridol, fludarabine and rituximab is a highly active regimen in indolent B-cell lymphoproliferative disorders including mantle cell lymphoma. Blood 106:944","journal-title":"Blood"},{"key":"3599_CR54","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/ajh.25333","volume":"94","author":"MR Litzow","year":"2019","unstructured":"Litzow MR, Wang XV, Carroll MP, Karp JE, Ketterling RP, Zhang Y, Kaufmann SH, Lazarus HM, Luger SM, Paietta EM, Pratz KW, Tun HW, Altman JK, Broun ER, Rybka WB, Rowe JM, Tallman MS (2019) A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. Am J Hematol 94:111\u2013117","journal-title":"Am J Hematol"},{"key":"3599_CR55","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1006\/bbrc.1994.1742","volume":"201","author":"MD Losiewicz","year":"1994","unstructured":"Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ (1994) Potent inhibition of CDC2 kinase activity by the flavonoid L86\u20138275. Biochem Biophys Res Commun 201:589\u2013595","journal-title":"Biochem Biophys Res Commun"},{"key":"3599_CR56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","volume":"17","author":"Q Lu","year":"2024","unstructured":"Lu Q, Kou D, Lou S, Ashrafizadeh M, Aref AR, Canadas I, Tian Y, Niu X, Wang Y, Torabian P, Wang L, Sethi G, Tergaonkar V, Tay F, Yuan Z, Han P (2024) Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy. J Hematol Oncol 17:16","journal-title":"J Hematol Oncol"},{"key":"3599_CR57","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1158\/1078-0432.CCR-11-3203","volume":"18","author":"JJ Luke","year":"2012","unstructured":"Luke JJ, D\u2019Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Maki RG, de Stanchina E, Musi E, Singer S, Schwartz GK (2012) The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res 18:2638\u20132647","journal-title":"Clin Cancer Res"},{"key":"3599_CR58","doi-asserted-by":"crossref","unstructured":"Mason KA, Hunter NR, Raju U, Ariga H, Husain A, Valdecanas D, Neal R, Ang KK, Milas L (2004) Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse. Int J Radiat Oncol Biol Phys 59:1181\u20131189","DOI":"10.1016\/j.ijrobp.2004.03.003"},{"key":"3599_CR59","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10637-005-6728-x","volume":"23","author":"F Mayer","year":"2005","unstructured":"Mayer F, Mueller S, Malenke E, Kuczyk M, Hartmann JT, Bokemeyer C (2005) Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines. Invest New Drugs 23:205\u2013211","journal-title":"Invest New Drugs"},{"key":"3599_CR61","first-page":"249","volume":"18","author":"K Miyashita","year":"2006","unstructured":"Miyashita K, Shiraki K, Fuke H, Inoue T, Yamanaka Y, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T (2006) The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Int J Mol Med 18:249\u2013256","journal-title":"Int J Mol Med"},{"key":"3599_CR62","doi-asserted-by":"crossref","unstructured":"Morgan DO (1995) Principles of CDK regulation. Nature 374:131-4","DOI":"10.1038\/374131a0"},{"key":"3599_CR63","doi-asserted-by":"publisher","unstructured":"Morris DG, Bramwell VH, Turcotte R, Figueredo AT, Blackstein ME, Verma S, Matthews S, Eisenhauer EA (2006) A phase II study of flavopiridol in patients with previously untreated advanced soft tissue sarcoma. Sarcoma 2006:64374. https:\/\/doi.org\/10.1155\/SRCM\/2006\/64374","DOI":"10.1155\/SRCM\/2006\/64374"},{"key":"3599_CR64","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0960-894X(00)00156-6","volume":"10","author":"KK Murthi","year":"2000","unstructured":"Murthi KK, Dubay M, McClure C, Brizuela L, Boisclair MD, Worland PJ, Mansuri MM, Pal K (2000) Structure\u2013activity relationship studies of flavopiridol analogues. Bioorg Med Chem Lett 10:1037\u20131041","journal-title":"Bioorg Med Chem Lett"},{"key":"3599_CR65","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1002\/chir.20925","volume":"22","author":"D Myatt","year":"2010","unstructured":"Myatt D, Johnson L, Baumli S, Siligardi G (2010) The binding of flavopiridol to blood serum albumin. Chirality 22:E40\u2013E43","journal-title":"Chirality"},{"key":"3599_CR66","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10600-016-1686-4","volume":"52","author":"R Nadirov","year":"2016","unstructured":"Nadirov R, Nadirov K, Bimbetova GZ, Nadirova ZK (2016) Synthesis and cytotoxic activity of new flavopiridol analogs. Chem Nat Compd 52:499\u2013500","journal-title":"Chem Nat Compd"},{"key":"3599_CR67","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/S0040-4020(01)90352-7","volume":"44","author":"RG Naik","year":"1988","unstructured":"Naik RG, Kattige S, Bhat S, Alreja B, de Souza N, Rupp R (1988) An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from Dysoxylum binectariferum: isolation, structure and total synthesis. Tetrahedron 44:2081\u20132086","journal-title":"Tetrahedron"},{"key":"3599_CR68","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","volume":"83","author":"DJ Newman","year":"2020","unstructured":"Newman DJ, Cragg GM (2020) Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019. J Nat Prod 83:770\u2013803","journal-title":"J Nat Prod"},{"key":"3599_CR69","doi-asserted-by":"publisher","first-page":"e13792","DOI":"10.1371\/journal.pone.0013792","volume":"5","author":"W Ni","year":"2010","unstructured":"Ni W, Ji J, Dai Z, Papp A, Johnson AJ, Ahn S, Farley KL, Lin TS, Dalton JT, Li X (2010) Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1\/OATP1B1 in flavopiridol disposition. PLoS One 5:e13792","journal-title":"PLoS One"},{"key":"3599_CR70","doi-asserted-by":"publisher","unstructured":"Nicolaou KC, Pfefferkorn JA, Roecker AJ, Cao G-Q, Barluenga S, Mitchell HJ (2000) Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of benzopyrans. J Am Chem Soc 122(41):9939\u20139953. https:\/\/doi.org\/10.1021\/ja002033k","DOI":"10.1021\/ja002033k"},{"key":"3599_CR71","doi-asserted-by":"publisher","first-page":"114428","DOI":"10.1016\/j.biopha.2023.114428","volume":"161","author":"G Ozkan","year":"2023","unstructured":"Ozkan G, G\u00fcnal-K\u00f6ro\u011flu D, Karadag A, Capanoglu E, Cardoso SM, Al-Omari B, Calina D, Sharifi-Rad J, Cho WC (2023) A mechanistic updated overview on lycopene as potential anticancer agent. Biomed Pharmacother 161:114428","journal-title":"Biomed Pharmacother"},{"key":"3599_CR72","doi-asserted-by":"publisher","first-page":"8858","DOI":"10.1158\/0008-5472.CAN-06-0808","volume":"66","author":"C Palacios","year":"2006","unstructured":"Palacios C, Yerbes R, L\u00f3pez-Rivas A (2006) Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res 66:8858\u20138869","journal-title":"Cancer Res"},{"key":"3599_CR73","first-page":"6655","volume":"37","author":"A Pawlak","year":"2017","unstructured":"Pawlak A, de Miguel D, Kutkowska J, Obmi\u0144ska-Mrukowicz B, Rapak A, Lostao LM (2017) Flavopiridol strongly sensitizes canine lymphoma cells to TRAIL-induced apoptosis. Anticancer Res 37:6655\u20136665","journal-title":"Anticancer Res"},{"key":"3599_CR74","first-page":"2637","volume":"113","author":"MA Phelps","year":"2009","unstructured":"Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM (2009) Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood, the Journal of the American Society of Hematology 113:2637\u20132645","journal-title":"Blood, the Journal of the American Society of Hematology"},{"key":"3599_CR75","doi-asserted-by":"publisher","first-page":"e0239315","DOI":"10.1371\/journal.pone.0239315","volume":"15","author":"N Pinto","year":"2020","unstructured":"Pinto N, Prokopec SD, Ghasemi F, Meens J, Ruicci KM, Khan IM, Mundi N, Patel K, Han MW, Yoo J (2020a) Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models. PLoS One 15:e0239315","journal-title":"PLoS One"},{"key":"3599_CR76","doi-asserted-by":"publisher","first-page":"e0239315","DOI":"10.1371\/journal.pone.0239315","volume":"15","author":"N Pinto","year":"2020","unstructured":"Pinto N, Prokopec SD, Ghasemi F, Meens J, Ruicci KM, Khan IM, Mundi N, Patel K, Han MW, Yoo J, Fung K, Macneil D, Mymryk JS, Datti A, Barrett JW, Boutros PC, Ailles L, Nichols AC (2020b) Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models. PLoS One 15:e0239315","journal-title":"PLoS One"},{"key":"3599_CR77","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ejmech.2019.07.041","volume":"180","author":"F Pojero","year":"2019","unstructured":"Pojero F, Poma P, Span\u00f2 V, Montalbano A, Barraja P, Notarbartolo M (2019) Targeting multiple myeloma with natural polyphenols. Eur J Med Chem 180:465\u2013485","journal-title":"Eur J Med Chem"},{"key":"3599_CR78","doi-asserted-by":"publisher","first-page":"216307","DOI":"10.1016\/j.canlet.2023.216307","volume":"570","author":"Y Qin","year":"2023","unstructured":"Qin Y, Ashrafizadeh M, Mongiardini V, Grimaldi B, Crea F, Rietdorf K, Gy\u0151rffy B, Klionsky DJ, Ren J, Zhang W, Zhang X (2023) Autophagy and cancer drug resistance in dialogue: pre-clinical and clinical evidence. Cancer Lett 570:216307","journal-title":"Cancer Lett"},{"key":"3599_CR79","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM (2018) Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 18:452\u2013464","journal-title":"Nat Rev Cancer"},{"key":"3599_CR80","doi-asserted-by":"publisher","first-page":"e01675","DOI":"10.1016\/j.heliyon.2019.e01675","volume":"5","author":"S Saisomboon","year":"2019","unstructured":"Saisomboon S, Kariya R, Vaeteewoottacharn K, Wongkham S, Sawanyawisuth K, Okada S (2019) Antitumor effects of flavopiridol, a cyclin-dependent kinase inhibitor, on human cholangiocarcinoma in vitro and in an in vivo xenograft model. Heliyon 5:e01675","journal-title":"Heliyon"},{"key":"3599_CR81","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1186\/s12889-024-18529-3","volume":"24","author":"JV Santos","year":"2024","unstructured":"Santos JV, Padron-Monedero A, Bikbov B, Grad DA, Plass D, Mechili EA, Gazzelloni F, Fischer F, Sulo G, Ngwa CH, Noguer-Zambrano I, Pe\u00f1alvo JL, Haagsma JA, Kissimova-Skarbek K, Monasta L, Ghith N, Sarmiento-Suarez R, Hrzic R, Haneef R, O\u2019Caoimh R, Cuschieri S, Mondello S, Kabir Z, Freitas A, Devleesschauwer B (2024) The state of health in the European Union (EU-27) in 2019: a systematic analysis for the Global Burden of Disease study 2019. BMC Public Health 24:1374","journal-title":"BMC Public Health"},{"key":"3599_CR82","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","volume":"133","author":"MA Sanz","year":"2019","unstructured":"Sanz MA, Fenaux P, Tallman MS, Estey EH, L\u00f6wenberg B, Naoe T, Lengfelder E, D\u00f6hner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Ad\u00e8s L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F (2019) Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 133:1630\u20131643","journal-title":"Blood"},{"key":"3599_CR83","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1200\/JCO.2002.08.080","volume":"20","author":"GK Schwartz","year":"2002","unstructured":"Schwartz GK, O\u2019Reilly E, Ilson D, Saltz L, Sharma S, Tong W, Maslak P, Stoltz M, Eden L, Perkins P, Endres S, Barazzoul J, Spriggs D, Kelsen D (2002) Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 20:2157\u20132170","journal-title":"J Clin Oncol"},{"key":"3599_CR84","doi-asserted-by":"crossref","unstructured":"Sedlacek H (2001) Mechanisms of action of flavopiridol. Crit Rev Oncol\/Hemato 38:139-170","DOI":"10.1016\/S1040-8428(00)00124-4"},{"key":"3599_CR85","first-page":"1143","volume":"9","author":"H Sedlacek","year":"1996","unstructured":"Sedlacek H, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A (1996) Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 9:1143\u20131168","journal-title":"Int J Oncol"},{"key":"3599_CR86","doi-asserted-by":"crossref","unstructured":"Senderowicz AM (1999) Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Investig New Drugs 17:313-320","DOI":"10.1023\/A:1006353008903"},{"key":"3599_CR87","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1200\/JCO.1998.16.9.2986","volume":"16","author":"AM Senderowicz","year":"1998","unstructured":"Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16:2986\u20132999","journal-title":"J Clin Oncol"},{"key":"3599_CR88","doi-asserted-by":"crossref","unstructured":"Shapiro GI (2004) Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 10:4270s-4275s","DOI":"10.1158\/1078-0432.CCR-040020"},{"key":"3599_CR89","unstructured":"Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch Jr TJ, Rollins BJ (2001) A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 7:1590-1599"},{"key":"3599_CR90","doi-asserted-by":"publisher","unstructured":"Sharma E, Attri DC, Sati P, Dhyani P, Szopa A, Sharifi-Rad J, Hano C, Calina D, Cho WC(2022) Recent updates on anticancer mechanisms of polyphenols. Front Cell Dev Biol 10:1005910.\u00a0https:\/\/doi.org\/10.3389\/fcell.2022.1005910","DOI":"10.3389\/fcell.2022.1005910"},{"key":"3599_CR91","doi-asserted-by":"publisher","first-page":"1026377","DOI":"10.3389\/fonc.2022.1026377","volume":"12","author":"A Theyab","year":"2022","unstructured":"Theyab A, Alsharif KF, Alzahrani KJ, Oyouni AAA, Hawsawi YM, Algahtani M, Alghamdi S, Alshammary AF (2022) New insight into strategies used to develop long-acting G-CSF biologics for neutropenia therapy. Front Oncol 12:1026377","journal-title":"Front Oncol"},{"key":"3599_CR92","doi-asserted-by":"publisher","unstructured":"Tomaszewski JE, Smith AC, Covey JM, Donohue SJ, Rhie JK, Schweikart KM (2002) CHAPTER 17 - Relevance of preclinical pharmacology and toxicology to phase I trial extrapolation techniques: relevance of animal toxicology. In: Baguley BC, Kerr DJ (eds) Anticancer drug development, Academic Press 301\u2013328. https:\/\/doi.org\/10.1016\/B978-012072651-6\/50018-8","DOI":"10.1016\/B978-012072651-6\/50018-8"},{"key":"3599_CR93","doi-asserted-by":"crossref","unstructured":"Vollset SE, Ababneh HS, Abate YH, Abbafati C, Abbasgholizadeh R, Abbasian M, Abbastabar H, Abd Al Magied AHA, Abd Elhafeez S, Abdelkader A, Abdelmasseh M, Abd-Elsalam S, Abdi P, Abdollahi M, Abdoun M, Abdullahi A, Abebe M, Abiodun O, Aboagye RG, Abolhassani H, Abouzid M, Aboye GB, Abreu LG, Absalan A, Abualruz H, Abubakar B, Abukhadijah HJJ, Addolorato G, Adekanmbi V, Adetunji CO, Adetunji JB, Adeyeoluwa TE, Adha R, Adhikary RK, Adnani QES, Adzigbli LA, Afrashteh F, Afzal MS, Afzal S, Agbozo F, Agodi A, Agrawal A, Agyemang-Duah W, Ahinkorah BO, Ahlstrom AJ, Ahmad A, Ahmad F, Ahmad MM, Ahmad S, Ahmad S, Ahmed A, Ahmed A, Ahmed H, Ahmed S, Ahmed SA, Akinosoglou K, Akkaif MA, Akrami AE, Akter E, Al Awaidy S, Al Hasan SM, Al Mosa AS, Al Ta'ani O, Al Zaabi OAM, Alahdab F, Alajlani MM, Al-Ajlouni Y, Alalalmeh SO, Al-Aly Z, Alam K, Alam N, Alam T, Alam Z, Al-Amer RM, Alanezi FM, Alanzi TM, Albakri A, Aldhaleei WA, Aldridge RW, Alemohammad SY, Alemu YM, Al-Gheethi AAS, Al-Hanawi MK, Ali A, Ali A, Ali I, Ali MU, Ali R, Ali, SSS, Ali VE, Ali W, Al-Ibraheem A, Alicandro G, Alif SM, Aljunid SM, Alla F, Almazan JU, Al-Mekhlafi HM, Alqutaibi AY, Alrawashdeh A et al (2024) Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet, 403, 2204-2256.","DOI":"10.1016\/S0140-6736(24)00685-8"},{"key":"3599_CR94","first-page":"753","volume":"55","author":"ME Wall","year":"1995","unstructured":"Wall ME, Wani MC (1995) Camptothecin and taxol: discovery to clinic\u2013thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 55:753\u2013760","journal-title":"Cancer Res"},{"key":"3599_CR95","doi-asserted-by":"publisher","first-page":"100672","DOI":"10.1016\/j.blre.2020.100672","volume":"44","author":"AH Wei","year":"2020","unstructured":"Wei AH, Roberts AW, Spencer A, Rosenberg AS, Siegel D, Walter RB, Caenepeel S, Hughes P, McIver Z, Mezzi K, Morrow PK, Stein A (2020) Targeting MCL-1 in hematologic malignancies: rationale and progress. Blood Rev 44:100672","journal-title":"Blood Rev"},{"key":"3599_CR96","doi-asserted-by":"publisher","first-page":"9179","DOI":"10.1200\/JCO.2004.01.0660","volume":"23","author":"JA Whitlock","year":"2005","unstructured":"Whitlock JA, Krailo M, Reid JM, Ruben SL, Ames MM, Owen W, Reaman G (2005) Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children\u2019s Oncology Group Study. J Clin Oncol 23:9179\u20139186","journal-title":"J Clin Oncol"},{"key":"3599_CR97","first-page":"4341","volume":"25","author":"A Wirger","year":"2005","unstructured":"Wirger A, Perabo FG, Burgemeister S, Haase L, Schmidt DH, Doehn C, Mueller SC, Jocham D (2005) Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Anticancer Res 25:4341\u20134347","journal-title":"Anticancer Res"},{"key":"3599_CR98","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/0006-2952(93)90590-S","volume":"46","author":"PJ Worland","year":"1993","unstructured":"Worland PJ, Kaur G, Stetler-Stevenson M, Sebers S, Sartor O, Sausville EA (1993) Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86\u20138275 in breast carcinoma cells: correlation with decreased H1 kinase activity. Biochem Pharmacol 46:1831\u20131840","journal-title":"Biochem Pharmacol"},{"key":"3599_CR99","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.08.008","volume":"365","author":"X Yang","year":"2009","unstructured":"Yang X, Zhao X, Phelps MA, Piao L, Rozewski DM, Liu Q, Lee LJ, Marcucci G, Grever MR, Byrd JC, Dalton JT, Lee RJ (2009) A novel liposomal formulation of flavopiridol. Int J Pharm 365:170\u2013174","journal-title":"Int J Pharm"},{"key":"3599_CR100","doi-asserted-by":"crossref","unstructured":"Yang Y, Liu L, Tian Y, Gu M, Wang Y, Ashrafizadeh M, Reza Aref A, Ca\u00f1adas I, Klionsky DJ, Goel A, Reiter RJ, Wang Y, Tambuwala M, Zou J (2024) Autophagy-driven regulation of cisplatin response in human cancers: exploring molecular and cell death dynamics. Cancer Lett 587:216659","DOI":"10.1016\/j.canlet.2024.216659"},{"key":"3599_CR101","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.3892\/ol.2013.1291","volume":"5","author":"Y Yao","year":"2013","unstructured":"Yao Y, Shi J, Zhang Z, Zhang F, Ma R, Zhao Y (2013) The radiation-sensitizing effect of flavopiridol in the esophageal cancer cell line Eca109. Oncol Lett 5:1872\u20131876","journal-title":"Oncol Lett"},{"key":"3599_CR102","first-page":"1822","volume":"63","author":"C Yu","year":"2003","unstructured":"Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P, Grant S (2003) The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase\/Akt-dependent process. Can Res 63:1822\u20131833","journal-title":"Can Res"},{"key":"3599_CR103","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.2174\/138920102012190919103433","volume":"20","author":"F Zalazar","year":"2019","unstructured":"Zalazar F, Luca PD, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E (2019) Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. Curr Pharm Biotechnol 20:1072\u20131072","journal-title":"Curr Pharm Biotechnol"},{"key":"3599_CR104","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.leukres.2015.10.010","volume":"39","author":"JF Zeidner","year":"2015","unstructured":"Zeidner JF, Karp JE (2015) Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia. Leuk Res 39:1312\u20131318","journal-title":"Leuk Res"},{"key":"3599_CR105","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1345\/aph.1A162","volume":"36","author":"S Zhai","year":"2002","unstructured":"Zhai S, Senderowicz AM, Sausville EA, Figg WD (2002) Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother 36:905\u2013911","journal-title":"Ann Pharmacother"},{"key":"3599_CR106","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1182\/blood-2004-05-1709","volume":"105","author":"M Zhang","year":"2005","unstructured":"Zhang M, Zhang Z, Goldman CK, Janik J, Waldmann TA (2005) Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. Blood 105:1231\u20131236","journal-title":"Blood"},{"key":"3599_CR107","first-page":"48","volume":"2","author":"XH Zhang","year":"2021","unstructured":"Zhang XH, Hsiang J, Rosen ST (2021) Flavopiridol (alvocidib), a cyclin-dependent kinases (CDKs) inhibitor, found synergy effects with niclosamide in cutaneous T-cell lymphoma. J Clin Haematol 2:48","journal-title":"J Clin Haematol"},{"key":"3599_CR108","first-page":"1166","volume":"10","author":"F Zhao","year":"2017","unstructured":"Zhao F, Xie Z, Yang Y, Li N, Wang X, Zhao F (2017) Down-regulation of anti-apoptosis protein livin promotes HMR1275 (flavopiridol)-induced apoptosis of endometrial carcinoma cell line ishikawa. Int J Clin Exp Pathol 10:1166\u20131171","journal-title":"Int J Clin Exp Pathol"},{"key":"3599_CR109","first-page":"175","volume":"56","author":"OM Zlatian","year":"2015","unstructured":"Zlatian OM, Comanescu MV, Rosu AF, Rosu L, Cruce M, Gaman AE, Calina CD, Sfredel V (2015) Histochemical and immunohistochemical evidence of tumor heterogeneity in colorectal cancer. Rom J Morphol Embryol 56:175\u2013181","journal-title":"Rom J Morphol Embryol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03599-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03599-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03599-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:24:04Z","timestamp":1744219444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03599-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":107,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3599"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03599-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}